Sjogren’s Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Gilead Sciences, Incyte Corporation, Novartis Pharmaceuticals, GlaxoSmithKline, Janssen Research & Development, LLC
The Sjogren’s syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Sjogren’s syndrome market dynamics.
DelveInsight’s “Sjogren’s syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Sjogren’s syndrome, historical and forecasted epidemiology as well as the Sjogren’s syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Sjogren’s syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sjogren’s syndrome Market Insights
Some of the key facts of the Sjogren’s syndrome Market Report:
The Sjogren’s syndrome market size was valued ~USD 1,900 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In November 2024, Johnson & Johnson (J&J) has announced encouraging findings from the Phase II DAHLIAS trial evaluating nipocalimab, a neonatal Fc receptor (FcRn) blocker, for the treatment of moderate-to-severe Sjögren’s disease (SjD). This placebo-controlled, multicenter, double-blind study examined the efficacy of nipocalimab in adults with primary Sjögren’s syndrome.
Novartis and Amgen are leading companies in the Sjogren’s syndrome market, with their drugs CFZ533 (iscalimab) and VIB4920 (dazodalibep) projected to achieve the highest revenue across the 7MM by 2034.
Across the 7MM, approximately 1.5 million diagnosed prevalent cases of Sjogren’s syndrome were recorded in 2023, with this number anticipated to grow over the forecast period (2024–2034).
In the US, antigen-specific cases were most commonly associated with auto-antibodies positivity, followed by anti-Ro/SSA positivity and anti-La/SSB positivity in 2023.
In 2023, the United States recorded the highest number of treated cases of Sjogren’s syndrome, while Japan reported the lowest, with approximately 54,000 treated cases. These figures are projected to increase by 2034.
Within the EU4 and the UK, Sjogren’s syndrome predominantly affected females, with the United Kingdom reporting the highest number of gender-specific cases in 2023.
Key Sjogren’s syndrome Companies: ADVANZ Pharma, Daiichi Sankyo, Novartis, Amgen, Bristol Myers Squibb, Dompe Farmaceutici, and others
Key Sjogren’s syndrome Therapies: SALAGEN (pilocarpine), EVOXAC (cevimeline), CFZ 533 (iscalimab), VIB4920 (dazodalibep), SOTYKTU (deucravacitinib), VAY736 (ianalumab), OXERVATE (cenegermin),and others
Sjogren’s syndrome Overview
The two most prevalent symptoms of Sjogren’s syndrome, an immune system illness, are dry eyes and a dry mouth. The syndrome frequently coexists with other immune system diseases like lupus and rheumatoid arthritis. Sjogren’s syndrome often affects your mucous membranes and moisture-secreting glands in your mouth and eyes first, which causes less saliva and tears to be produced.
Although Sjogren’s syndrome can strike at any age, most cases of the condition are detected in patients over the age of 40. In women, the illness is far more prevalent. The goal of Sjogren’s syndrome treatment is to reduce symptoms.
Get a Free sample for the Sjogren’s syndrome Market Report:
https://www.delveinsight.com/report-store/sjogrens-syndrome-market-size
Sjogren’s syndrome Epidemiology Segmentation:
The Sjogren’s syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Sjogren’s syndrome
Prevalent Cases of Sjogren’s syndrome by severity
Gender-specific Prevalence of Sjogren’s syndrome
Diagnosed Cases of Episodic and Chronic Sjogren’s syndrome
Download the report to understand which factors are driving Sjogren’s syndrome epidemiology trends @ Sjogren’s syndrome Epidemiological Insights
Sjogren’s syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sjogren’s syndrome market or expected to get launched during the study period. The analysis covers Sjogren’s syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Sjogren’s syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Sjogren’s syndrome Therapies and Key Companies
SALAGEN (pilocarpine): ADVANZ Pharma
EVOXAC (cevimeline): Daiichi Sankyo
CFZ 533 (iscalimab): Novartis
VIB4920 (dazodalibep): Amgen
SOTYKTU (deucravacitinib): Bristol Myers Squibb
VAY736 (ianalumab): Novartis
OXERVATE (cenegermin): Dompe Farmaceutici
To know more about Sjogren’s syndrome treatment, visit @ Sjogren’s syndrome Medications
Sjogren’s syndrome Market Drivers
Increasing Prevalence
Advancements in Diagnostics
Sjogren’s syndrome Pipeline Therapies
Supportive Regulatory Environment
Growing Awareness
Sjogren’s syndrome Market Barriers
Limited Treatment Options
High Treatment Costs
Side Effects of Therapies
Delayed Diagnosis
Lack of Awareness
Scope of the Sjogren’s syndrome Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Sjogren’s syndrome Therapies: SALAGEN (pilocarpine), EVOXAC (cevimeline), CFZ 533 (iscalimab), VIB4920 (dazodalibep), SOTYKTU (deucravacitinib), VAY736 (ianalumab), OXERVATE (cenegermin), and others
Sjogren’s syndrome Therapeutic Assessment: Sjogren’s syndrome current marketed and Sjogren’s syndrome emerging therapies
Sjogren’s syndrome Market Dynamics: Sjogren’s syndrome market drivers and Sjogren’s syndrome market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Sjogren’s syndrome Unmet Needs, KOL’s views, Analyst’s views, Sjogren’s syndrome Market Access and Reimbursement
Discover more about therapies set to grab major Sjogren’s syndrome market share @ Sjogren’s syndrome Treatment Landscape
Table of Contents
1. Sjogren’s syndrome Market Report Introduction
2. Executive Summary for Sjogren’s syndrome
3. SWOT analysis of Sjogren’s syndrome
4. Sjogren’s syndrome Patient Share (%) Overview at a Glance
5. Sjogren’s syndrome Market Overview at a Glance
6. Sjogren’s syndrome Disease Background and Overview
7. Sjogren’s syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Sjogren’s syndrome
9. Sjogren’s syndrome Current Treatment and Medical Practices
10. Sjogren’s syndrome Unmet Needs
11. Sjogren’s syndrome Emerging Therapies
12. Sjogren’s syndrome Market Outlook
13. Country-Wise Sjogren’s syndrome Market Analysis (2020–2034)
14. Sjogren’s syndrome Market Access and Reimbursement of Therapies
15. Sjogren’s syndrome Market drivers
16. Sjogren’s syndrome Market barriers
17. Sjogren’s syndrome Appendix
18. Sjogren’s syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: Nevada Country: United StatesWebsite: https://www.delveinsight.com/
